Active MK-4 and MK-7, carrageenan free
- Supports bone, cardiovascular health and normal blood clotting
- Provides the ideal ratio of MK-4 and MK-7 for better efficacy
- Oil based softgel enhances absorption of Vitamin K
Vitamin K is an essential vitamin needed for cardiovascular, bone, and liver health. Vitamin K2 breaks down into two forms, namely MK-4 and MK-7. While MK-4 is the active form of vitamin K2 used by the body, MK-7 has recently been shown to provide good results at low doses. AOR’s Vitamin K2 offers both forms of vitamin K2 in equal amounts, while most formulas on the market only focus on one or the other.
Vitamin K is best known for its essential role in blood clotting, but it also has important functions in the skeletal system, cardiovascular, bone, and liver health. Vitamin K2 consists of a family of compounds that include MK-4 and MK-7, forms that are abundant in foods such as natto and various cheeses. Recent studies have suggested that vitamin K2 is better absorbed and persists longer in the plasma than vitamin K1 (found in plants) and may be more appropriate for supplementation.
Unique to many other supplements, AOR’s Vitamin K2 is derived from soy-free sources for potential dietary concerns. Vitamin K2 is also formulated in a carrageenan-free vegan softgel, offering optimal absorption and suitability for various dietary preferences or restrictions, while promoting environmental sustainability.
Vitamin K2 from AOR™ provides MK-4 and MK-7, the two optimal forms of Vitamin K2. Formulated using AOR’s patent pending VSoftgel™ technology for superior absorption.*
AOR™ guarantees that all ingredients have been declared on the label. Made without wheat, gluten, corn, peanuts, sesame seeds, mustard, dairy, sulfites, eggs, soy, fish, shellfish or any animal byproduct.
Take one softgel daily with/without food, or as directed by a qualified health care practitioner.
Consult a health care practitioner before use if you’re pregnant, lactating, have a medical condition, or if you’re taking any medication (blood thinners). Keep out of reach of children.
- Bone health
- Calcium absorption
- Cardiovascular health
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Other Ingredients: organic coconut oil, microcrystalline cellulose, and sunflower vitamin E tocopherols.
Softgel: tapioca starch, glycerin, and purified water.
Contains: tree nuts (coconut).
Iwamoto J, Takeda T, Sato Y, Shen CL, Yeh JK. Beneficial effect of pretreatment and treatment continuation with risedronate and vitamin K2 on cancellous bone loss after ovariectomy in rats: a bone histomorphometry study. J Nutr Sci Vitaminol (Tokyo). 2006 Oct;52(5):307-15.
Iwamoto J, Takeda T, Sato Y. Menatetrenone (vitamin K2) and bone quality in the treatment of postmenopausal osteoporosis. Nutr Rev. 2006 Dec;64(12):509-17.
Kakizaki S, Sohara N, Sato K, Suzuki H, Yanagisawa M, Nakajima H, Takagi H, Naganuma A, Otsuka T, Takahashi H, Hamada T, Mori M. Preventive effects of vitamin K on recurrent disease in patients with hepatocellular carcinoma arising from hepatitis C viral infection. J Gastroenterol Hepatol. 2007 Apr;22(4):518-22.
Knapen MH, Drummen NE, Smit E, Vermeer C, Theuwissen E. Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. Osteoporos Int. 2013 Sep;24(9):2499-507.
Knapen MH, Schurgers LJ, Vermeer C. Vitamin K(2) supplementation improves hip bone geometry and bone strength indices in postmenopausal women. Osteoporos Int. 2007 Jul;18(7):963-72.
Ozaki I, Zhang H, Mizuta T, Ide Y, Eguchi Y, Yasutake T, Sakamaki T, Pestell RG, Yamamoto K. Menatetrenone, a vitamin K2 analogue, inhibits hepatocellular carcinoma cell growth by suppressing cyclin D1 expression through inhibition of nuclear factor kappaB activation. Clin Cancer Res. 2007 Apr 1;13(7):2236-45.
Purwosunu Y, Muharram , Rachman IA, Reksoprodjo S, Sekizawa A. Vitamin K2 treatment for postmenopausal osteoporosis in Indonesia. J Obstet Gynaecol Res. 2006 Apr;32(2):230-4.
Sato T, Schurgers LJ, Uenishi K. Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women. Nutr J. 2012 Nov 12;11:93.
Theuwissen E, Teunissen KJ, Spronk HM, Hamulyák K, Ten Cate H, Shearer MJ, Vermeer C, Schurgers LJ. J Thromb Haemost. Effect of low-dose supplements of menaquinone-7 (vitamin K2 ) on the stability of oral anticoagulant treatment: dose-response relationship in healthy volunteers. 2013 Jun;11(6):1085-92.